Gain access to the world’s largest and fastest growing cannabinoid medicines markets

Zelira Therapeutics offers investors exposure to a rapidly growing global industry at a very attractive valuation with significant value drivers.

Zelira’s revenue generation continues through multiple revenue streams from licensing payments, royalties and fast-tracking commercialisation through a disruptive ‘Launch, Learn & Develop’ model.

With a footprint in the US, Australia, UK and the EU, a portfolio of branded and validated products already launched, and a pipeline of Rx and OTC products underway, Zelira Therapeutics is well-positioned for continued growth.

For investor-related information please contact Ronn Bechler at Automic Group
Ph: +61 (0) 400 009 774 E:

Start typing and press Enter to search

Shopping Cart